CPI, an independent technology innovation center and founding member of the UK Government’s High Value Manufacturing Catapult, has completed Project GAIA, establishing a large-scale manufacturing process for Pyocin S5, a protein antibiotic that could treat lung disease in patients with cystic fibrosis. The scaled-up production will enable the University of Glasgow – who developed the small-scale process – to progress clinical evaluation of this promising treatment.    Infection with the bacteriu...